CYP3A4*1B but Not CYP3A5*3 as Determinant of Long-Term Tacrolimus Dose Requirements in Spanish Solid Organ Transplant Patients
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252011327 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Julia Concha und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Faculty of Health Sciences, Universidad San Jorge, E-50830 Villanueva de Gállego, Zaragoza, Spain. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Tacrolimus, Immunosuppressive Agents, Organ Transplantation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Departamento de Ciencia, Universidad y Sociedad del Conocimiento, Gobierno de Aragón (Spain), Novaltia SCOOP.
Abstract (Originalsprache)
Tacrolimus (TAC) is a commonly used immunosuppressive drug in solid organ transplantation. Pharmacogenetics has been demonstrated before to be decisive in TAC pharmacotherapy. The CYP3A5*3 variant has been reported to be the main determinant of TAC dose requirements; however, other polymorphisms have also proven to be influential, especially in CYP3A5 non-expressor patients. The aim of this study is to evaluate the influence of genetic polymorphisms in TAC therapy in a cohort of Spanish transplant recipients. Genetic analysis including ten polymorphic variants was performed, and demographic and clinical data and pharmacotherapy of 26 patients were analyzed. No significant differences were found in weight-adjusted dose between CYP3A5 expressors and non-expressors (0.047 mg/kg vs. 0.044 mg/kg), while they were found for carriers of the CYP3A4*1B allele (0.101 mg/kg; p < 0.05). The results showed that patients with at least one CYP3A4*1B allele had a higher TAC dose and lower blood concentration. Dose-adjusted TAC blood levels were also lower in CYP3A4*1B carriers compared to non-carriers (0.72 ng/mL/mg vs. 2.88 ng/mL/mg). These results support the independence of CYP3A5*3 and CYP3A4*1B variants as determinants of dose requirements despite the linkage disequilibrium present between the two. The variability in genotype frequency between ethnicities may be responsible for the discrepancy found between studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Faculty of Health Sciences, Universidad San Jorge, E-50830 Villanueva de Gállego, Zaragoza, Spain.
ORCID-Profile: Julia Concha, Estela Sangüesa, María Pilar Ribate, Cristina B García
Förderung
- Departamento de Ciencia, Universidad y Sociedad del Conocimiento
- Gobierno de Aragón (Spain)
- Novaltia SCOOP
- Industrias Químicas del Ebro S.A.
Zitieren
APA
Concha, J., Sangüesa, E., Ribate, M. P., & García, C. B. (2024). CYP3A4*1B but Not CYP3A5*3 as Determinant of Long-Term Tacrolimus Dose Requirements in Spanish Solid Organ Transplant Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252011327
Vancouver
Concha J, Sangüesa E, Ribate MP, García CB. CYP3A4*1B but Not CYP3A5*3 as Determinant of Long-Term Tacrolimus Dose Requirements in Spanish Solid Organ Transplant Patients. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252011327
BibTeX
@article{Concha2024,
author = {Concha, Julia and Sangüesa, Estela and Ribate, María Pilar and García, Cristina B},
title = {CYP3A4*1B but Not CYP3A5*3 as Determinant of Long-Term Tacrolimus Dose Requirements in Spanish Solid Organ Transplant Patients},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252011327}
}
EUVIMED